Dynamic Changes of Fecal Calprotectin and Related Clinical Factors in Neonates

Ji Sook Park, Jae Young Cho, Changyeong Chung, Seong Hee Oh, Hyun-jeong Do, Ji-Hyun Seo, Jae Young Lim, Chan-Hoo Park, Hyang-Ok Woo, and Hee-Shang Youn

Objective: Fecal calprotectin (FC) has been widely used for a clinical marker of intestinal inflammation in children and adults. However, the clinical usefulness has not been determined in neonates. The purpose of this study was to investigate the change of FC and associated clinical factors in neonates.

Methods and Materials: In total, 146 neonates among 472 admissions to our NICU between 2018 and 2019 were included, and 242 stool samples were collected. FC was measured in the first, second, and third–fourth week after birth, respectively, using commercial ELISA. The clinical characteristics were reviewed from medical records. Statistical analyses were performed to analyze associated factors regarding on changes of fecal calprotectin.

Results: A wide range from 5.5 to 6,000 mg/kg of FC was observed in neonates. FCs during neonatal period were not correlated with the gestational age at birth or birth weight. The meconial calprotectin was higher than FCs after 2 weeks of age (n = 134, 418.06 vs. 243.12 in the second week and 259.58 in the third week after birth). Meconial calprotectin was associated with birth weight and meconium stained amniotic fluid. FC during the neonatal period decreased with postnatal week (−464.93 ± 158.02 at third–fourth week after birth compared with the 1st week, P = 0.004) and breast milk (−337.27 ± 150.51 compared with formula milk, P = 0.026).

Conclusion: Fecal calprotectin tended to decrease with postnatal week during the neonatal period, and breast milk could affect more decrease of FC.

Keywords: calprotectin, neonate, meconium, breast milk, postnatal week

INTRODUCTION

Calprotectin is a 36.5-kDa calcium- and zinc-binding protein found mostly in neutrophils, monocytes, and macrophages and involved in the regulation of inflammation (1, 2). This protein is stable in the feces for 1 week at room temperature, and commercial enzyme-linked immunosorbent assay (ELISA) kits are available for extraction and analysis of small stool samples, ~0.1 g of stool. Fecal calprotectin (FC) concentration is directly proportional to neutrophil migration toward the gastrointestinal tract and closely correlates with leukocyte excretion in the feces (3). FC has been
studied as a noninvasive and useful marker for bowel inflammation in children and adults such as inflammatory bowel disease and other organic intestinal and allergic disorders (3–8). For adults and children, <50 µg/g of FC in stool has been considered within normal limits (9). However, FC concentration has age-dependent variation in children, especially those younger than 4 years, and increases in infants (10, 11). Normally, a high level of FC was reported in healthy neonates, and the usefulness of this marker remains controversial in the neonatal period (2). Although the clinical usefulness of FC in newborns has been studied in diverse aspects including gestational period, birth weight (BW), delivery modes, diet, antibiotic treatment, necrotizing enterocolitis (NEC), or gut microbiota, it has been inconclusive because of high interindividual variations, inhomogeneous subjects, and different sampling times according to previous studies (12–16). Yang et al. (17) reported that serial changes of FC could be affected by minor or major systemic and gastrointestinal stress in 14 very-low-birth-weight infants. However, Zoonen et al. (18) reported that serial FCs could not predict NEC in 40 preterm infants including 10 infants with NEC and 30 controls. There is still controversy on the clinical meaning of FC and serial changes of FC in preterm and term neonates. Thus, the purpose of this study was to investigate associating clinical factors with serial changes of FC during the neonatal period.

METHOD

Subjects and Stool Collection
Among 472 admissions at the neonatal intensive care unit (NICU) in our hospital between May 2018 and October 2019, stool samples for FC were collected prospectively from 146 neonates born at 25–40 weeks of gestation, with parent’s consent. In total, 242 stool samples were collected, with 134 in the first, 67 in the second, and 41 in the third–fourth weeks of life. Stool samples were stored at 4°C without preservative and measured within 5 days of collection using commercial ELISA (Calprolab™ Calprotectin ELISA, Calpro AS, Norway) following the manufacturer’s instruction. Two or more serial stools were collected from 64 among 146 neonates.

Clinical Data Collection
The clinical characteristics were retrospectively reviewed from medical records. The prenatal and perinatal clinical factors were investigated as follows.

1. Multiple gestation such as two or more fetuses in one pregnancy.
2. Meconium-stained amniotic fluid (AF) such as meconium pass before giving birth.
3. Prolonged premature rupture of membrane (PPROM) such as rupture of amniotic membrane over 18 h before birth.
4. Maternal hypertensive condition such as essential hypertension, pregnancy-induced hypertension (PIH), eclampsia, or preeclampsia.
5. Respiratory distress syndrome (RDS) of newborn such as ground glass opacity of lungs on chest X-ray with tachypnea and/or desaturation.
6. Use of antibiotics such as any kind of antibiotic treatment for suspicious or culture-proven sepsis during the neonatal period.
7. Neonatal jaundice such as unconjugated hyperbilirubinemia that needs phototherapy in preterm and term neonates (19).
8. Intestinal distress such as gastrointestinal symptoms or signs leading to interrupted enteral feeding and suspected or definite NEC based on modified Bell’s classification (20).
9. Days of full feeding such as postnatal days until fed enterally with 120 ml/kg/day.
10. Breast milk (BM) feeding such as being fed with BM exclusively or partially with BM being >1/2 of the total amount of feeding volume.

Statistical Analysis
Statistical analyses were conducted using SPSS® version 25.0 (IBM, NY, US), and GraphPad Prism 6 (Graph-Pad Software, CA, USA) was used for graphics. Normality of the continuous values was tested by Kolmogorov–Smirnov and Shapiro–Wilk tests. The continuous variables were presented as the mean and standard deviation (SD) or median and interquartile range (IQR). Comparisons of FC according to clinical factors were performed by independent t-test or the Mann–Whitney U-test. Correlation between FC and continuous variables was performed by the Spearman rho test. The categorical data were presented as the number and proportion (%). Multivariable linear or nonlinear logistic regression analysis was conducted to investigate an association between clinical factors and the level of FC. We also checked the multicollinearity between the factors for adjustment using correlation coefficients and excluded one when the coefficient was more than 0.7. The changes in FC concentration according to clinical factors during the neonatal period were investigated using a linear mixed model (LMM) or generalized linear mixed-effect model (GLMM), a repeated-measures covariance pattern model with unstructured covariance within the subjects. The P-value was set as <0.05.

Ethics Statement
The protocol of this study was reviewed and approved by the institutional review board of our hospital (GNUH 2020-02-004). Informed consent was waived by the board.

RESULTS

Clinical Characteristics
The clinical characteristics were described in Table 1. In total, 146 neonates were enrolled and born at a mean of 34.6 ± 3.5 weeks of gestation (range: 25±3/7–40±3/7). Among them, preterm neonates born before 37 weeks of gestation were 109 (74.7%). Mean BW was 2.2 ± 0.8 kg (range: 0.6–4.3), and low-birth-weight infants weighing less than 2.5 kg were 93 (63.7%). Twenty-eight (19.2%) were born vaginally. Males were 68 (46.6%). Mean Apgar score at 5 min was 8.8 ± 1.3. Obstetric problems occurred in 89
pregnancies, which were maternal hypertensive disorder (24.7%, 36 of 146 neonates), gestational diabetes mellitus (GDM, 15.1%, 22 of 146 neonates), PPROM (11.0%, 16 of 146 neonates), and meconium pass in utero (10.3%, 15 of 146 neonates) in that order. Rates of BM feeding was 75.3% (110 of 146 neonates), meconium-stained AF (17.5%), and low BW or being small for gestation (13.8%), in prematurity (59.6%), maternal condition affecting baby’s health twins or triplets.

Chief complaints at admission among 146 neonates were prematurity (59.6%), maternal condition affecting baby’s health (17.5%), and low BW or being small for gestation (13.8%), in that order. Rates of BM feeding was 75.3% (110 of 146 neonates), meconium-stained AF (17.5%), and low BW or being small for gestation (13.8%), in prematurity (59.6%), maternal condition affecting baby’s health twins or triplets.

Forty-three neonates (29.5%) among 146 neonates were born as twins or triplets.

TABLE 1 | Clinical characteristics and level of fecal calprotectin in total subjects (N = 146).

| Variables                     | Mean ± SD, N (%) | Median (IQR) | Min, Max |
|-------------------------------|------------------|--------------|----------|
| **Prenatal variables**        |                  |              |          |
| Multiple gestation            | 43 (29.5)        |              |          |
| Meconium-stained AF           | 15 (10.3)        |              |          |
| Maternal hypertensive disorder| 36 (24.7)        |              |          |
| PPROM                         | 16 (11.0)        |              |          |
| GDM                           | 22 (15.1)        |              |          |
| **Perinatal variables**       |                  |              |          |
| Gestational age, weeks        | 34.56 ± 3.47     | 35.00        | 25.57, 40.43 |
| Birth weight, kg              | 2.21 ± 0.82      | 2.20 (1.56, 2.76) | 0.60, 4.31 |
| Male                          | 68 (46.6)        |              |          |
| S’-AS                         | 8.79 ± 1.34      | 9.00         | 3, 10    |
| Vaginal delivery              | 28 (19.2)        |              |          |
| **Postnatal variables**       |                  |              |          |
| RDS                           | 54 (37.0)        |              |          |
| Jaundice                      | 27 (18.5)        |              |          |
| Use of antibiotics            | 95 (65.1)        |              |          |
| Intestinal distress           | 17 (11.6)        |              |          |
| Breast milk                   | 110 (75.3)       |              |          |
| Days till full feeding (120 ml/kg) | 9.67 ± 12.02   | 5.0 (3.0, 10.0) | 1, 75 |
| Hospital stays, day           | 26.34 ± 25.93    | 16.0 (9.0, 35.0) | 2, 156 |
| Weight at discharge, kg       | 2.77 ± 0.61      | 2.66 (2.37, 3.11) | 1.08, 5.84 |
| Mortality                     | 2 (1.4)          |              |          |
| Fecal calprotectin, mg/kg stool | 341.68 ± 687.39 | 164.65        | 5.50, >6,000 |
| Week 1 (n = 134)              | 418.06 ± 864.89  | 197.75        | 6.10, >6,000 |
| Week 2 (n = 67)               | 243.12 ± 328.80  | 123.00        | 5.50, 1,792.0 |
| Weeks 3–4 (n = 41)            | 259.58 ± 368.18  | 162.25        | 20.6, 2,061.0 |

SD, standard deviation; IQR, interquartile range; meconium-stained AF; meconium-stained amniotic fluid; PPROM, prolonged rupture of membrane; GDM, gestational diabetes mellitus; S’-AS, Apgar score at 5 min; RDS, respiratory distress syndrome; jaundice, unconjugated hyperbilirubinemia requiring phototherapy.

Concentration of FC

FCs were measured in the first, second, and third–fourth weeks after birth, and a total of 242 FCs were measured from 146 neonates. The FC of the first week was mean 418.06 ± 864.89 mg/kg of stool and was collected from 134 neonates on mean day of 2.14 ± 1.87 after birth (median 1.0, IQR: 1.0–3.0). The second-week FC was mean 243.12 ± 328.80 mg/kg of stool and was collected from 67 neonates on mean day of 10.03 ± 0.43 after birth (median 9.0, IQR: 8.0–12.0). The third–fourth week FC was mean 259.58 ± 368.18 mg/kg of stool and was collected on mean day of 21.29 ± 1.07 after birth (median 21.0, IQR: 15.8–24.0). The lowest level of FC was 5.5, and the highest one was over 6,000 mg/kg. Changes of FC in individual subject are shown in Figure 1.

The mean concentration of FC during neonatal period was 341.68 ± 687.39 mg/kg, in total. FCs were not correlated with the gestational age (GA, r = −0.125, P = 0.151) or BW (r = −0.144, P = 0.097).

Associating Factor With High Meconial Calprotectin Concentration

The first-week FC was measured by meconium since feces were collected at mean 2.14 ± 1.87 days after birth (median 1.0 day, IQR: 1.0–3.0). Meconial calprotectin was higher than later FCs (Table 1, Figures 1, 2). Meconial calprotectin was higher in females (626.43 ± 1,313.04 mg/kg) than in males (175.85 ± 178.03 mg/kg, P < 0.001). We performed stepwise multivariable linear or nonlinear regression analysis to investigate associating prenatal or perinatal factors with meconial calprotectin. Of them, lower BW (−284.25 ± 91.88 mg/kg per kilogram increase, P = 0.002) and meconium-stained AF (464.70 ± 232.14 mg/kg, P = 0.047) were associated with changes in FC.
high concentration of meconial calprotectin (Table 2). GA and gender were not considered as associating factors with meconial calprotectin because GA had high collinearity with BW ($r = 0.872, P < 0.001$) and BW was different according to gender in this study (females: $2.09 \pm 0.78$ kg, males: $2.48 \pm 0.78$ kg, $P = 0.005$).

Changes of FC and Associated Clinical Factors

We performed univariable analyses using LMM for repeated FC outcomes among 64 neonates with two or more consecutive FCs. FC decreased after 1 week of life, and the associating factors with decreased change of FC during neonatal period were males ($-350.786 \pm 130.211$ mg/kg, $P = 0.008$), antibiotics ($-429.308 \pm 1,358.823$ mg/kg, $P = 0.002$), and BM ($-382.927 \pm 149.532$ mg/kg, $P = 0.011$; Table 3). GA, BW, or obstetric problems did not affect changes in FC during the neonatal period. RDS, jaundice, or intestinal distress including suspected and definite NEC did not show statistically significant effect on changes in FC during the neonatal period (Table 3). When we performed multivariable GLMM of the significantly associating factors on univariable analyses with intercept, BM ($-337.266 \pm 150.505$, $P = 0.026$), antibiotics ($-410.904 \pm 141.688$, $P = 0.004$), and postnatal week (second week: $-416.386 \pm 138.002$, $P = 0.003$, and third–fourth weeks: $-464.934 \pm 158.024$, $P = 0.004$) were associated factors with decreased changes of FC during the neonatal period compared with each reference (Figure 2 and Table 4).

DISCUSSION

Neonatal FC showed wide ranges from 5.5 to more than 6,000 mg/kg of stool in this study. Individual FC changed dynamically during the neonatal period (Figure 1), and its changes were affected by time, kind of diet, and use of antibiotics (Figure 2 and Table 4).

The authors observed that the level of FC from the first-week stool was higher than that of later FCs. The first FC in this study could reflect meconial calprotectin since it was measured on mean 2.14 \pm 1.87$ days after birth and preterm and term neonates could pass meconium for about 2.0–7.8 days (21). Previous studies reported that calprotectin in meconium correlated with GA at birth, BW, and poor 5'-Apgar score and that meconial calprotectin could reflect intraterine environment, intestinal immaturity, and hypoxic–ischemic damage of the intestinal mucosa (22, 23). In our study, the high meconial calprotectin was associated with lower BW and meconium-stained AF when stepwise multivariable linear or nonlinear regression analysis was performed (Table 2). However, it was not correlated with GA ($r = -0.125, P = 0.151$), 5'-Apgar score ($r = -0.057, P = 0.513$) or postnatal days in the first week ($r = -0.136, P = 0.117$) unlike previous studies (22, 23). Several kinds of perinatal factors including delivery mode, feeding volume, or general conditions were reported with FC previously; however, the results were inconclusive (14, 17, 24). The lack of agreement on the results of associating perinatal factors with meconial calprotectin may have originated from diverse conditions and background in the perinatal period. Based on our results, intrauterine distress such as meconium-stained AF and intestinal immaturity in neonates with lower BW could influence high meconial calprotectin level (Table 2). However, meconium comprises materials ingested during the fetal period, including intestinal epithelial cells, AF, lanugo, and mucous. And the diverse cellular composition may affect the high concentration of meconial calprotectin because

TABLE 2 | Associating prenatal or perinatal factors with calprotectin in meconium using multivariable linear or nonlinear regression analysis (stepwise, $N = 134$).

| Variables | B ± SE (mg/kg) | P-value 95% Confidence interval |
|-----------|----------------|---------------------------------|
| Birthweight, per kg increase | $-284.245 \pm 91.881$ | 0.002 | $-466.035$ to $-102.455$ |
| Meconium-stained AF | $464.969 \pm 232.143$ | 0.047 | 5.395 to 923.996 |

Dependent variable was fecal calprotectin within the first week. Abbreviation: SE, standard error; meconium-stained AF, meconium-stained amniotic fluid.
calprotectin can be expressed on the membrane of monocytes and mucosal epithelial cells besides the cytoplasm in neutrophils (2, 25).  

Gender, antibiotics, diet, and postnatal week were statistically associated with change of FC, when we performed univariable analyses (Table 3). Of those significant factors, BM, antibiotics, and postnatal week were associated with decreased changes of FC during the neonatal period when multivariable analysis using GLMM with intercept was performed (Figure 2 and Table 4). In this study, a significant drop of FC was observed after the first week, and the concentration was stable after the second week of life. Resolution of intrauterine distress (23), maturation of intestinal mucosa (22), establishment of intestinal microbiota (15), or change from meconium with diverse cellular or molecular compositions to transitional stool may affect the time trend of FC between the first and second weeks of life. 

FC decreased in neonates fed with BM (Tables 3 and 4, Figure 2). Selection bias may exist because meconial calprotectin of neonates fed with BM in later FCs was lower than that of neonates fed with formula milk (FM) in later FCs. However, FC increased in neonates fed with FM after the second week of life, contrary to the trend of FC in neonates fed with BM (Figure 2B). However, the influence of diet on FC is still conflicting (16, 24, 26, 27). The previous studies recruited various subjects including preterm and full-term infants aged 1 week and 5 months, and we enrolled 109 preterm and 37 full-term neonates born at 25−403 weeks of gestation for the neonatal period. The variation of inclusions according to the study designs may explain the conflicting results. Based on the previous report of Bifidobacterium lactis Bb12 and a significant decrease in calprotectin levels (12), probiotics in BM may lead to more decrease of FC than that in FM in this study. Further studies on the association between probiotics in BM and changes of FC are necessary. 

Use of prenatal or perinatal antibiotic treatments could negatively or positively affect FC in newborns (15, 28). In this study, antibiotic treatment seemed to negatively affect FC during the neonatal period statistically (Figure 2C and Table 4). But selection bias existed since neonates with antibiotic treatment had already lower concentration of meconial calprotectin than neonates without antibiotic treatment in later FCs (1,404.73 ± 471.23 vs. 322.37 ± 67.72 mg/kg, P = 0.033). Even though there was a selection bias on statistical analysis according to antibiotic treatment in this study, the result that neonates with high meconial calprotectin did not receive antibiotics in later FCs.

**Table 3** Changes of fecal calprotectin in neonates and associated clinical factors using univariable mixed analyses for repeated fecal calprotectin outcomes among 64 neonates with two or more consecutive fecal calprotectins.

| Variables                        | Estimate ± SE, mg/kg | P-values | 95% Confidence interval |
|----------------------------------|----------------------|----------|-------------------------|
| GA, per week increase            | −23.62 ± 17.361      | 0.176    | −57.913 10.665          |
| BW, per kg increase              | −137.669 ± 94.232    | 0.146    | −328.777 48.439         |
| Male*, female (reference)        | −350.786 ± 130.211   | 0.008    | −607.952 −93.619        |
| 5′-AS                            | −74.505 ± 43.771     | 0.091    | −160.953 11.942         |
| CS delivery, VD (reference)      | −42.635 ± 157.049    | 0.786    | −352.805 267.536        |
| Multigestation, single (reference)| 143.410 ± 139.563    | 0.306    | −132.227 419.046        |
| Meconium-stained AF, no (reference)| 315.144 ± 209.351    | 0.134    | −98.324 728.611         |
| Maternal hypertensive disorder, no (reference)| −182.278 ± 140.070 | 0.195    | −458.916 94.361         |
| PPROM, no (reference)            | 306.066 ± 180.297    | 0.092    | −50.019 662.151         |
| GDM, no (reference)              | −183.757 ± 184.587   | 0.321    | −548.315 180.802        |
| RDS, no (reference)              | 161.469 ± 132.739    | 0.226    | −100.715 423.653        |
| Jaundice, no (reference)         | 185.719 ± 144.642    | 0.201    | −99.948 471.387         |
| Antibiotics*, no (reference)     | −429.308 ± 135.823   | 0.002    | −697.559 −161.057       |
| Intestinal distress, no (reference)| 161.875 ± 148.166   | 0.276    | −130.751 454.501        |
| BM*, FM (reference)              | −382.927 ± 149.532   | 0.011    | −678.252 −87.603        |
| Days till full feeding (120 ml/kg/day), per day increase | 1.625 ± 3.687 | 0.660 | −5.661 8.910 |
| Hospital stays, per day increase | 1.207 ± 2.075        | 0.562    | −2.891 5.305            |
| Mortality, no (reference)        | −259.97 ± 372.944    | 0.487    | −996.537 476.590        |
| Postnatal week*, first (reference)| −427.870 ± 146.240  | 0.012    | −781.731 −74.008        |
| Second                           | −416.265 ± 164.270   | 0.037    | −813.755 −18.774        |

**Table 4** Associating clinical factor with changes of fecal calprotectin among 64 neonates with two or more consecutive fecal calprotectins by multivariable analysis using generalized linear effect model for repeated calprotectin outcomes.

| Variables                        | Estimate ± SE, mg/kg | P-values | 95% Confidence interval |
|----------------------------------|----------------------|----------|-------------------------|
| Intercept                        | 711.055 ± 409.573    | 0.085    | −98.178 1,520.289       |
| BW, per kg increase              | 12.489 ± 103.234     | 0.904    | −191.481 216.459        |
| Male, female (reference)         | −214.437 ± 128.449   | 0.097    | −468.226 39.352         |
| 5′-AS                            | −7.660 ± 46.070      | 0.888    | −98.886 83.366          |
| BM, FM (reference)               | −337.266 ± 150.505   | 0.026    | −634.633 −39.899        |
| Antibiotics, no (reference)      | −410.904 ± 141.688   | 0.004    | −690.851 −130.956       |
| Intestinal distress, no (reference) | 185.541 ± 163.982    | 0.260    | −138.455 509.537        |
| Postnatal week, first (reference)| −427.870 ± 146.240  | 0.012    | −781.731 −74.008        |
| Second                           | −464.934 ± 158.024   | 0.004    | −777.157 −152.710       |

BM, birth weight; 5′-AS, Apgar score at 5 min; BM, breast milk; FM, formula milk.

SE, standard error; GA, gestational age; BW, birth weight; 5′-AS, Apgar score at 5 min; CS, cesarean section; PPROM, prolonged rupture of membrane; GDM, gestational diabetes mellitus; RDS, respiratory distress syndrome; BM, breast milk; FM, formula milk.

*Variables were statistically significant factors associated with changes of fecal calprotectin during neonatal period on univariable analyses.
might indirectly suggest that calprotectin may be involved in the regulation of inflammation (2).

Studies of calprotectin as a marker of intestinal disease in neonates were reported given its utility in inflammatory bowel disease (14, 17, 18, 29–33). Some of the reported FCs could be a marker for intestinal permeability such as early diagnosis and resolution of gastrointestinal illnesses (14, 15, 17, 29, 30). However, FC for the purpose of early diagnosis or prognosis of NEC has conflicting results because of wide variations of cutoff points and wide interindividual and intravariation. However, FC is not necessary because of the low reliability of this study caused by the small number of inclusions. Many missing stools at each time point and selection bias in BM and the antibiotic treatment group were the other limitations. GLMM was used for analysis between clinical factors and changes in FC to compensate for the missing samples. Despite these limitations, the prospective nature of this study and collection of serial stool samples from individuals were our strengths.

In conclusion, FC during the neonatal period decreased with time regardless of GA at birth, BW, or other diseases. BM may contribute to lower FC levels. Decrease of FC with postnatal week and BM may be associated with transition of feces or establishment of intestinal microbiota. Regarding intestinal inflammation in neonates like NEC, clinical usefulness of FC was questionable unlike children and adults. We observed dynamic changes of FC during the neonatal period, and caution is necessary when FC is interpreted in neonates.

DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the article/supplementary material.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Institutional Review Board of the Gyeongsang National University Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS
JP: Designing and conducting the study, and drafting the manuscript. JC: Conducting the study. CC: Presenting the study and collecting data. SO: Collecting data and stool samples. HD: Collecting data and stool samples. J-HS: Interpreting data. JL: Interpreting data. C-HP: Designing the study and collecting data. H-Ow: Interpreting data. H-SY: Interpreting data. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by a biomedical research institute fund (GNUHBRIF-2018-0001) and a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2019R1G1A1100590).

ACKNOWLEDGMENTS
The statistical analyses in this study were supported by the medical research statistics of Gyeongsang National University Hospital.

REFERENCES
1. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. *Eur J Biochem.* (1983) 134:1–6. doi: 10.1111/j.1432-1033.1983.tb07722.x
2. Kapel N, Campeotto F, Kalach N, Baldassare M, Butel MJ, Dupont C. Faecal calprotectin in term and preterm neonates. *J Pediatr Gastroenterol Nutr.* (2010) 51:542–7. doi: 10.1097/MGP.0b013e3181e2ad72
3. Montalto M, Gallo A, Santoro L, D’Onofrio F, Landolfi R, Gasbarrini A. Role of fecal calprotectin in gastrointestinal disorders. *Eur Rev Med Pharmacol Sci.* (2013) 17:1569–82.
4. Tibble J, Teahon K, Thodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. *Gut.* (2000) 47:506–13. doi: 10.1136/gut.47.4.506
5. Trillo Belizon C, Ortega Paet E, Medina Claros AF, Rodriguez Sanchez I, Reina Gonzalez A, Vera Medialdea R, et al. Faecal calprotectin as an aid to the diagnosis of non-1gE mediated cow’s milk protein allergy. *An Pediatr (Barc).* (2016) 84:318–23. doi: 10.1016/j.anpede.2015.07.037
6. Merras-Salmio L, Kolho KL, Pelkonen AS, Kuitunen M, Makela MJ, Savilahvi E. Markers of gut mucosal inflammation and cow’s milk specific immunoglobulins in non-IgE cow’s milk allergy. *Clin Transl Allergy.* (2014) 4:8–7022–4–8. doi: 10.1186/2045-7022-4-8
7. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JI, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. *Am J Gastroenterol.* (2000) 95:2831–7. doi: 10.1111/j.1572-0241.2000.03194.x
8. Emanuel B, Christoph B. The use of fecal calprotectin as a biomarker in gastrointestinal disease. *Expert Rev Gastroenterol Hepatol.* (2014) 8:192–210. doi: 10.1586/17474142.2014.869476
9. Alibrahim B, Aljasser MI, Sall B. Fecal calprotectin use in inflammatory bowel disease and beyond: a mini-review. *Can J Gastroenterol Hepatol.* (2015) 29:157–63. doi: 10.1155/2015/950286
10. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. *J Pediatr Gastroenterol Nutr.* (2002) 34:323–4; author reply 4–5. doi: 10.1097/00005176-200203000-00022

11. Song JY, Lee YM, Choi YJ, Jeong SJ. Fecal calprotectin level in healthy children aged less than 4 years in South Korea. *J Clin Lab Anal.* (2017) 31:e22113. doi: 10.1002/jcla.22113

12. Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. *Pediatr Res.* (2008) 64:418–422. doi: 10.1203/PDR.0b013e3181b757fa

13. Bjorkstrom MV, Hall L, Soderlund S, Hakansson EG, Hakansson S, Domellof M. Intestinal flora in very low-birth weight infants. *Acta Paediatr.* (2009) 98:1762–7. doi: 10.1111/j.1651-2227.2009.01471.x

14.Josefsson S, Bunn SK, Domellof M. Fecal calprotectin in very low birth weight infants. *J Pediatr Gastroenterol Nutr.* (2007) 44:407–13. doi: 10.1097/MPG.0b013e3180320643

15. Rouge C, Butel MJ, Pilouquet H, Ferrarris L, Legrand A, Vodover M, et al. Fecal calprotectin excretion in preterm infants during the neonatal period. *PLoS One.* (2010) 5:e11083. doi: 10.1371/journal.pone.0011083

16. Li F, Ma J, Geng S, Wang J, Ren F, Sheng X. Comparison of the different kinds of feeding on the level of fecal calprotectin. *Early Hum Dev.* (2014) 90:471–3. doi: 10.1016/j.earhumdev.2014.06.005

17. Yang Q, Smith PB, Goldberg RN, Cotten CM. Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life. *Neonatology.* (2008) 94:267–71. doi: 10.1159/000151645

18. van Zoonen AGJF, Hulzebos CV, Muller Kobold AC, Kooi EMW, Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barto L, et al. Duration of meconium passage in preterm and term infants. *Arch Dis Child Fetal Neonatal Ed.* (2011) 96:663–8. doi: 10.1136/adc.2010.200824

19. Jeffry M. Chapter 35: Jaundice. In: Mhairi GM, Mary MKS, Martha DM, editors. Avery's Neonatology Pathophysiology and Management of the Newborn. Philadelphia, PA: Lippincott Williams & Wilkins. (2005) p. 768-846.

20. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. *Ann Surg.* (1978) 187:1–7. doi: 10.1097/00000658-197801000-00001

21. Bekkali N, Hamers SL, Schippers MR, Reitsma JB, Valerio PG, Van Toledo L, et al. Duration of meconium passage in preterm and term infants. *Arch Dis Child Fetal Neonatal Ed.* (2008) 93:F376–9. doi: 10.1136/adc.2008.138024

22. Laforgia N, Baldassarre ME, Pontrelli G, Indrio F, Altomare MA, Di Bitonto G, et al. Calprotectin levels in meconium. *Acta Paediatr.* (2003) 92:463–66. doi: 10.1111/j.1651-2227.2003.tb00579.x

23. Lisowska-Myjak B, Skarzynska E, Zytynska-Daniluk J. Calprotectin in serially collected meconium portions as a biomarker for intrauterine fetal environment. *Fetal Diagn Ther.* (2018) 43:68–71. doi: 10.1159/000472150

24. Campopoto F, Butel MJ, Kalach N, Derieux S, Aubert-Jacquin C, Barbot L, et al. High faecal calprotectin concentrations in newborn infants. *Arch Dis Child Fetal Neonatal Ed.* (2004) 89:F353–5. doi: 10.1136/adc.2002.023668

25. Striz I, Trebichavian I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. *Physiol Res.* (2004) 53:245–53.

26. Groer M, Ashmeade T, Louis-Jacques A, Beckstead J, Ji M. Relationships of feeding and mother’s own milk with fecal calprotectin levels in preterm infants. *Breastfeed Med.* (2016) 11:207–12. doi: 10.1089/bfm.2015.0115

27. Savino F, Castagno E, Calabrese R, Viola S, Oggero R, Miniero R. High faecal calprotectin levels in healthy, exclusively breast-fed infants. *Neonatology.* (2010) 97:299–304. doi: 10.1159/000355161

28. Loniewska B, Wegrzyn D, Adamek K, Kaczmarszyk M, Skonieczna-Zydecka K, Adler G, et al. The influence of maternal-foetal parameters on concentrations of zonulin and calprotectin in the blood and stool of healthy newborns during the first seven days of life. An observational prospective cohort study. *J Clin Med.* (2019) 8:473. doi: 10.3390/jcm8040473

29. Carroll D, Corfield A, Spicer R, Cairns P. Fecal calprotectin concentrations and diagnosis of necrotising enterocolitis. *Lancet.* (2003) 361:310–1. doi: 10.1016/S0140-6736(03)12333-1

30. Yoon JM, Park JY, Ko KO, Lim JW, Cheon EJ, Kim HJ. Fecal calprotectin concentration in neonatal necrotizing enterocolitis. *Korean J Pediatr.* (2014) 57:351–6. doi: 10.3345/kjp.2014.57.8.351

31. Zhang M, Zhang X, Zhang J. Diagnostic value of fecal calprotectin in preterm infants with necrotizing enterocolitis. *Clin Lab.* (2016) 62:863–9. doi: 10.7754/ClinLab.2015.150906

32. Baldassarre ME, Fanelli M, Lasorella ML, Laneve A, Grosso R, Falcone MR, et al. Fecal calprotectin (FC) in newborns: is it a predictive marker of gastrointestinal and/or allergic disease?. *Immunopharmacol Immunotoxicol.* (2011) 33:220–3. doi: 10.3109/08923973.2010.486035

33. Nakayunyongsuk W, Christofferson M, Stevenson DK, Sylvester G, Lee HC, Park KT. Point-of-care fecal calprotectin monitoring in preterm infants at risk for necrotizing enterocolitis. *J Pediatr.* (2018) 196:98–103.e1. doi: 10.1016/j.jpeds.2017.12.069

34. Goldstein GP, Sylvester KG. Biomarker discovery and utility in necrotizing enterocolitis. *Pediatric Clinics of North America.* (2019) 66. doi: 10.1016/j.pcl.2019.05.001

35. Copyright © 2020 Park, Cho, Chang, Oh, Do, Seo, Lim, Park, Woo and Youn. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.